Myotonic Dystrophy Market Expected to Grow Rapidly During the Forecast Period (2026-2036) as Pipeline Therapies Address Unmet Medical Needs | DelveInsight
The myotonic dystrophy market is expected to grow significantly due to the advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies such as Tideglusib (AMO-02; AMO Pharma), Delpacibart etedesiran (formerly AOC-1001; Novartis/Avidity Biosciences), NaMuscla (mexiletine; Lupin), and others.
LAS VEGAS, Sept. 23, 2026 /PRNewswire/ -- Recently published Myotonic Dystrophy Market Insights report includes a comprehensive understanding of current treatment practices, myotonic dystrophy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Myotonic Dystrophy Market Summary
Discover congenital myotonic dystrophy prevalence United States 2026 @ https://www.delveinsight.com/report-store/myotonic-dystrophy-market
Key Factors Driving the Growth of the Myotonic Dystrophy Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that if upcoming candidates demonstrate durable functional benefits, treatment adoption, diagnosis rates, and payer willingness to reimburse premium therapies are likely to increase, supporting long-term market growth.
Myotonic Dystrophy Market Analysis
Myotonic Dystrophy Competitive Landscape
Some of the myotonic dystrophy drugs under development include Tideglusib (AMO-02; AMO Pharma), Delpacibart etedesiran (formerly AOC-1001; Novartis/Avidity Biosciences), NaMuscla (mexiletine; Lupin), Zeleciment basivarsen (z-basivarsen; Dyne Therapeutics), PGN-EDODM1 (PepGen), VX-670 (Vertex Pharmaceuticals), SRP-1003 (Sarepta Therapeutics), ATX-01 (ARTHEx Biotech), JUV-161 (Juvena Therapeutics), MDL-202 (Modalis Therapeutics), and others.
AMO Pharma's AMO-02 is an orally administered small-molecule inhibitor of glycogen synthase kinase 3β (GSK3β) being developed for the treatment of congenital myotonic dystrophy. Preclinical and clinical studies have indicated its potential to restore GSK3β levels and reduce pathogenic mRNA associated with myotonic dystrophy type 1 (DM1). The therapy has received several regulatory designations from the US FDA, including Orphan Drug Designation (ODD), Fast Track Designation (FTD), and Rare Pediatric Disease (RPD) designation.
Del-desiran, Novartis/Avidity's lead Antibody Oligonucleotide Conjugate (AOC), is designed to address the underlying molecular cause of myotonic dystrophy type 1 by reducing disease-associated DMPK mRNA. The therapy consists of a TfR1-targeting monoclonal antibody conjugated to a small interfering RNA (siRNA). It has received Breakthrough Therapy Designation (BTD), Fast Track Designation (FTD), and Orphan Drug Designation (ODD) from the US FDA, as well as orphan designation in the European Union, underscoring its potential as a treatment for DM1.
The anticipated launch of these emerging therapies are poised to transform the myotonic dystrophy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the myotonic dystrophy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the myotonic dystrophy type 2 treatment @ Myotonic Dystrophy Treatment Market
Recent Developments in the Myotonic Dystrophy Market
Myotonic Dystrophy Epidemiology Segmentation
The myotonic dystrophy epidemiology section provides insights into the historical and current myotonic dystrophy patient pool and forecasted trends for the leading markets. Based on DelveInsight's estimates, in 2025, the diagnosed prevalent population of myotonic dystrophy in the United States was estimated to be approximately 57,000.
The myotonic dystrophy treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Myotonic Dystrophy Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Myotonic Dystrophy Market Size in 2025
USD 236 Million
Key Myotonic Dystrophy Companies
AMO Pharma, Novartis, Avidity Biosciences, Lupin, Dyne Therapeutics, PepGen, Vertex Pharmaceuticals, Sarepta Therapeutics, ARTHEx Biotech, Juvena Therapeutics, Modalis Therapeutics, and others
Key Myotonic Dystrophy Therapies
Tideglusib (AMO-02), Delpacibart etedesiran (formerly AOC-1001), NaMuscla (mexiletine), Zeleciment basivarsen (z-basivarsen), PGN-EDODM1, VX-670, SRP-1003, ATX-01, JUV-161, MDL-202, and others
Scope of the Myotonic Dystrophy Market Report
Download the report to understand the treatment for myotonic dystrophy @ Myotonic Dystrophy Drug Market
Table of Contents
1
Myotonic Dystrophy Market Key Insights
2
Myotonic Dystrophy Market Report Introduction
3
Myotonic Dystrophy Market Overview at a Glance
3.1
Market Share (%) Distribution of Myotonic Dystrophy by Therapies in 2025
3.2
Market Share (%) Distribution of Myotonic Dystrophy by Therapies in 2036
4
Methodology of Myotonic Dystrophy Epidemiology and Market
5
Executive Summary of Myotonic Dystrophy
6
Key events
7
Disease background and overview
7.1
Introduction
7.2
Clinical Manifestations
7.3
Classification
7.4
Etiology
7.5
Pathophysiology
7.6
Diagnosis
7.6.1
Differential diagnosis
7.7
Treatment
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Total Diagnosed Prevalent Cases of Myotonic Dystrophy in the 7MM
8.3
Assumption and Rationale
8.4
The United States
8.4.1
Diagnosed Prevalence of Myotonic Dystrophy in the United States
8.4.2
Type-Specific Diagnosed Cases of Myotonic Dystrophy in the United States
8.4.3
Type-Specific Diagnosed Cases of Myotonic Dystrophy Type 1 in the United States
8.4.4
Age-Specific Diagnosed Cases of Myotonic Dystrophy in the United States
8.4.5
Comorbidity-associated Diagnosed Cases with Myotonic Dystrophy in the United States
8.5
The EU4 and the UK
8.6
Japan
9
Patient Journey
10
Emerging Therapies
10.1
Key cross: Emerging
10.2
Tideglusib (AMO-02): AMO Pharma
10.2.1
Drug description
10.2.2
Other Development Activities
10.2.3
Clinical Trial Information
10.2.4
Safety and efficacy
10.2.5
Analyst Views
10.3
NaMuscla (mexiletine): Lupin
10.4
Delpacibart etedesiran: Avidity Biosciences
List to be continued in the report
11
Myotonic Dystrophy Market: 7 Major Market Analysis
11.1
Key Findings
11.2
Key Myotonic Dystrophy Market Forecast Assumptions
11.3
Myotonic Dystrophy Market Outlook
11.4
Attribute Analysis
11.5
Total Market Size of Myotonic Dystrophy in the 7MM
11.6
The United States Myotonic Dystrophy Market Size
11.6.1
Total Market Size of Myotonic Dystrophy in the United States
11.6.2
Market Size of Myotonic Dystrophy by Therapies in the United States
11.7
EU4 and the UK Myotonic Dystrophy Market Size
11.7
Japan Myotonic Dystrophy Market Size
12
Key Opinion Leaders' Views
13
Unmet Need
14
SWOT Analysis
15
Myotonic Dystrophy Market Access and Reimbursement
16
Bibliography
17
Acronyms and Abbreviations
Related Reports
Myotonic Dystrophy Clinical Trial Analysis
Myotonic Dystrophy Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myotonic dystrophy companies, including AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, and others.
Duchenne Muscular Dystrophy Market
Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Duchenne muscular dystrophy companies, including FibroGen, Santhera Pharmaceutical, Italfarmaco, ReveraGen BioPharma, Cumberland Pharmaceuticals, Sarepta Therapeutics, Antisense Therapeutics, Capricor Therapeutics, and others.
Limb-Girdle Muscular Dystrophy Market
Limb-Girdle Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key limb-girdle muscular dystrophy companies, including ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
Cone Rod Dystrophy Market
Cone Rod Dystrophy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cone rod dystrophy companies, including Sparing Vision, Beacon Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP